Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2018 1
2019 1
2021 1
2022 9
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K. Yamasoba D, et al. Cell. 2022 Jun 9;185(12):2103-2115.e19. doi: 10.1016/j.cell.2022.04.035. Epub 2022 May 2. Cell. 2022. PMID: 35568035 Free PMC article.
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, Morioka Y, Nao N, Nasser H, Uriu K, Kosugi Y, Tsuda M, Orba Y, Sasaki M, Shimizu R, Kawabata R, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Ikeda T, Irie T, Matsuno K, Tanaka S, Fukuhara T, Sato K. Suzuki R, et al. Among authors: yamasoba d. Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1. Nature. 2022. PMID: 35104835 Free PMC article.
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.
Yamasoba D, Uriu K, Plianchaisuk A, Kosugi Y, Pan L, Zahradnik J; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Sato K. Yamasoba D, et al. Lancet Infect Dis. 2023 Jun;23(6):655-656. doi: 10.1016/S1473-3099(23)00278-5. Epub 2023 May 3. Lancet Infect Dis. 2023. PMID: 37148902 Free PMC article. No abstract available.
Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, Kobiyama K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K. Kimura I, et al. Among authors: yamasoba d. Cell. 2022 Oct 13;185(21):3992-4007.e16. doi: 10.1016/j.cell.2022.09.018. Epub 2022 Sep 14. Cell. 2022. PMID: 36198317 Free PMC article.
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, Zepeda SK, Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J, Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T, Mallery DL, Charles OJ; CITIID-NIHR BioResource COVID-19 Collaboration; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ecuador-COVID19 Consortium; Bowen JE, Joshi A, Walls AC, Jackson L, Martin D, Smith KGC, Bradley J, Briggs JAG, Choi J, Madissoon E, Meyer KB, Mlcochova P, Ceron-Gutierrez L, Doffinger R, Teichmann SA, Fisher AJ, Pizzuto MS, de Marco A, Corti D, Hosmillo M, Lee JH, James LC, Thukral L, Veesler D, Sigal A, Sampaziotis F, Goodfellow IG, Matheson NJ, Sato K, Gupta RK. Meng B, et al. Among authors: yamasoba d. Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022 Feb 1. Nature. 2022. PMID: 35104837 Free PMC article.
Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
Tamura T, Yamasoba D, Oda Y, Ito J, Kamasaki T, Nao N, Hashimoto R, Fujioka Y, Suzuki R, Wang L, Ito H, Kashima Y, Kimura I, Kishimoto M, Tsuda M, Sawa H, Yoshimatsu K, Yamamoto Y, Nagamoto T, Kanamune J, Suzuki Y, Ohba Y; Genotype to Phenotype Japan (G2P-Japan) Consortium; Yokota I, Matsuno K, Takayama K, Tanaka S, Sato K, Fukuhara T. Tamura T, et al. Among authors: yamasoba d. Commun Biol. 2023 Jul 24;6(1):772. doi: 10.1038/s42003-023-05081-w. Commun Biol. 2023. PMID: 37488344 Free PMC article.
Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
Kimura I, Yamasoba D, Nasser H, Ito H, Zahradnik J, Wu J, Fujita S, Uriu K, Sasaki J, Tamura T, Suzuki R, Deguchi S, Plianchaisuk A, Yoshimatsu K, Kazuma Y, Mitoma S, Schreiber G, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Takaori-Kondo A; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Shirakawa K, Takayama K, Irie T, Hashiguchi T, Nakagawa S, Fukuhara T, Saito A, Ikeda T, Sato K. Kimura I, et al. Among authors: yamasoba d. J Virol. 2023 Oct 31;97(10):e0101123. doi: 10.1128/jvi.01011-23. Epub 2023 Oct 5. J Virol. 2023. PMID: 37796123 Free PMC article.
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Anraku Y, Kimura I, Ito J, Yamasoba D, Nasser H, Toyoda M, Nagata K, Uriu K, Kosugi Y, Fujita S, Shofa M, Monira Begum M, Shimizu R, Oda Y, Suzuki R, Ito H, Nao N, Wang L, Tsuda M, Yoshimatsu K, Kuramochi J, Kita S, Sasaki-Tabata K, Fukuhara H, Maenaka K, Yamamoto Y, Nagamoto T, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Ueno T, Schreiber G, Takaori-Kondo A; Genotype to Phenotype Japan (G2P-Japan) Consortium; Shirakawa K, Sawa H, Irie T, Hashiguchi T, Takayama K, Matsuno K, Tanaka S, Ikeda T, Fukuhara T, Sato K. Saito A, et al. Among authors: yamasoba d. Cell Host Microbe. 2022 Nov 9;30(11):1540-1555.e15. doi: 10.1016/j.chom.2022.10.003. Epub 2022 Oct 18. Cell Host Microbe. 2022. PMID: 36272413 Free PMC article.
Virological characteristics of the SARS-CoV-2 KP.2 variant.
Kaku Y, Uriu K, Kosugi Y, Okumura K, Yamasoba D, Uwamino Y, Kuramochi J, Sadamasu K, Yoshimura K, Asakura H, Nagashima M; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Sato K. Kaku Y, et al. Among authors: yamasoba d. Lancet Infect Dis. 2024 May 20:S1473-3099(24)00298-6. doi: 10.1016/S1473-3099(24)00298-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38782005 No abstract available.
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.
Kimura I, Kosugi Y, Wu J, Zahradnik J, Yamasoba D, Butlertanaka EP, Tanaka YL, Uriu K, Liu Y, Morizako N, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Ueno T, Takaori-Kondo A, Schreiber G, Arase H; Genotype to Phenotype Japan (G2P-Japan) Consortium; Motozono C, Saito A, Nakagawa S, Sato K. Kimura I, et al. Among authors: yamasoba d. Cell Rep. 2022 Jan 11;38(2):110218. doi: 10.1016/j.celrep.2021.110218. Epub 2021 Dec 18. Cell Rep. 2022. PMID: 34968415 Free PMC article.
19 results